ABSTRACT

I-123/I-131 labeled metaiodobenzylguanidine (MIBG) is one of the theranostic agents maintaining both imaging and therapy of tumors derived from neural crest cells. Despite its higher cost, I-123 MIBG is the agent of choice because of its higher imaging quality, lower radiation exposure and more favorable dosimetry allowing high-quality single-photon emission computed tomography (SPECT) imaging. Theoretically, I-131 MIBG therapy can be used in the therapy of all tumors with MIBG uptake. However I-131 MIBG therapy is predominantly used in the treatment of neuroblastoma and malign/inoperable pheochromocytomas/paragangliomas. In this review, it is aimed to focus on the theranostic efficiency, clinical utility and the side effects of MIBG.